Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus

…, IN Bruce, D Isenberg, DJ Wallace… - Arthritis & …, 2012 - Wiley Online Library
Objective The Systemic Lupus International Collaborating Clinics (SLICC) group revised
and validated the American College of Rheumatology (ACR) systemic lupus erythematosus (…

2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus

…, C Vasconcelos, EM Vital, DJ Wallace… - Arthritis & …, 2019 - Wiley Online Library
Objective To develop new classification criteria for systemic lupus erythematosus ( SLE )
jointly supported by the European League Against Rheumatism ( EULAR ) and the American …

American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis

…, JT Merrill, DJ Wallace, J Yazdany… - Arthritis care & …, 2012 - Wiley Online Library
In the US, approximately 35% of adults with systemic lupus erythematosus (SLE) have
clinical evidence of nephritis at the time of diagnosis, with an estimated total of 50–60% …

A phase III, randomized, placebo‐controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus …

…, M Petri, O Zamani, R Cervera, DJ Wallace… - Arthritis & …, 2011 - Wiley Online Library
Objective To assess the efficacy/safety of the B lymphocyte stimulator inhibitor belimumab
plus standard therapy compared with placebo plus standard therapy in active systemic lupus …

Efficacy and safety of rituximab in moderately‐to‐severely active systemic lupus erythematosus: the randomized, double‐blind, phase II/III systemic lupus …

JT Merrill, CM Neuwelt, DJ Wallace… - … : Official Journal of …, 2010 - Wiley Online Library
Objective B cells are likely to contribute to the pathogenesis of systemic lupus erythematosus
(SLE), and rituximab induces depletion of B cells. The Exploratory Phase II/III SLE …

[HTML][HTML] Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis

…, M Petri, GS Gilkeson, DJ Wallace… - … England Journal of …, 2005 - Mass Medical Soc
Background Since anecdotal series and small, prospective, controlled trials suggest that
mycophenolate mofetil may be effective for treating lupus nephritis, larger trials are desirable. …

Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis …

…, S Wassenberg, R Weier, DJ Wallace… - Arthritis & …, 2005 - Wiley Online Library
Objective To investigate the efficacy and tolerability of infliximab therapy for the articular and
dermatologic manifestations of active psoriatic arthritis (PsA). Methods One hundred four …

A short course of BG9588 (anti–CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis

…, R Furie, S Manzi, GG Illei, DJ Wallace… - Arthritis & …, 2003 - Wiley Online Library
Objective CD40–CD40 ligand (CD40L) interactions play a significant role in the production
of autoantibodies and tissue injury in lupus nephritis. We performed an open‐label, multiple‐…

The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes

…, SR Levine, E Waterhouse, DJ Wallace… - Arthritis and …, 1999 - pure.johnshopkins.edu
Objective. To develop a standardized nomenclature system for the neuropsychiatric syndromes
of systemic lupus erythematosus (NPSLE). Methods. An international, multidisciplinary …

A phase II, randomized, double‐blind, placebo‐controlled, dose‐ranging study of belimumab in patients with active systemic lupus erythematosus

DJ Wallace, W Stohl, RA Furie, JR Lisse… - Arthritis Care & …, 2009 - Wiley Online Library
Objective To assess the safety, tolerability, biologic activity, and efficacy of belimumab in
combination with standard of care therapy (SOC) in patients with active systemic lupus …